206 related articles for article (PubMed ID: 24782116)
1. Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib.
Lauring B; Li XS; Liu Y; Corr C; Lazarus N; Cote J; Larson P; Levonas AO; Lasseter KC; Preston RA; Smith WB; Lai E; Wagner JA
J Clin Pharmacol; 2014 Nov; 54(11):1247-55. PubMed ID: 24782116
[TBL] [Abstract][Full Text] [Related]
2. Effect of hepatic and renal impairment on the pharmacokinetics of dalcetrapib: altered distribution of the active thiol?
Phelan M; Anzures-Cabrera J; Carlile DJ; Rowell L; Kuhlmann O; Arold G; Robson R; Bentley D
Clin Pharmacokinet; 2013 Apr; 52(4):255-65. PubMed ID: 23400900
[TBL] [Abstract][Full Text] [Related]
3. Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib.
Small DS; Zhang W; Royalty J; Cannady EA; Downs D; Ortega D; Suico JG
Eur J Clin Pharmacol; 2016 May; 72(5):563-72. PubMed ID: 26857125
[TBL] [Abstract][Full Text] [Related]
4. Influence of renal and hepatic impairment on the pharmacokinetic and pharmacodynamic properties and tolerability of fluticasone furoate and vilanterol in combination.
Allen A; Davis A; Hardes K; Tombs L; Kempsford R
Clin Ther; 2012 Dec; 34(12):2316-32. PubMed ID: 23200625
[TBL] [Abstract][Full Text] [Related]
5. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
Narasimhan NI; Dorer DJ; Davis J; Turner CD; Marbury TC; Sonnichsen D
Cancer Chemother Pharmacol; 2014 Aug; 74(2):341-8. PubMed ID: 24934866
[TBL] [Abstract][Full Text] [Related]
8. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women.
Jannuzzo MG; Poggesi I; Spinelli R; Rocchetti M; Cicioni P; Buchan P
Cancer Chemother Pharmacol; 2004 Jun; 53(6):475-81. PubMed ID: 15014897
[TBL] [Abstract][Full Text] [Related]
9. Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
Iwamoto M; Hanley WD; Petry AS; Friedman EJ; Kost JT; Breidinger SA; Lasseter KC; Robson R; Lunde NM; Wenning LA; Stone JA; Wagner JA
Antimicrob Agents Chemother; 2009 May; 53(5):1747-52. PubMed ID: 19223645
[TBL] [Abstract][Full Text] [Related]
10. Asenapine pharmacokinetics in hepatic and renal impairment.
Peeters P; Bockbrader H; Spaans E; Dogterom P; Lasseter K; Marbury T; Gibson GL; de Greef R
Clin Pharmacokinet; 2011 Jul; 50(7):471-81. PubMed ID: 21651314
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, in patients with moderate hepatic impairment.
Wang YH; Liu F; Luk JA; Nirula A; Johnson-Levonas AO; Lasseter KC; Marbury TC; Lunde NM; Wagner JA; Lai E
J Clin Pharmacol; 2011 Mar; 51(3):406-12. PubMed ID: 20484612
[TBL] [Abstract][Full Text] [Related]
13. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
[TBL] [Abstract][Full Text] [Related]
14. Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects.
Krishna R; Stypinski D; Ali M; Garg A; Gendrano IN; Maes A; DeGroot B; Liu Y; Li S; Connolly SM; Wagner JA; Stoch SA
Biopharm Drug Dispos; 2011 Dec; 32(9):525-9. PubMed ID: 22031172
[TBL] [Abstract][Full Text] [Related]
15. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
[TBL] [Abstract][Full Text] [Related]
16. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
Schöller-Gyüre M; Kakuda TN; De Smedt G; Woodfall B; Berckmans C; Peeters M; Hoetelmans RM
Clin Ther; 2010 Feb; 32(2):328-37. PubMed ID: 20206790
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
Zhao Q; Iyer GR; Verhaeghe T; Truyen L
J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
[TBL] [Abstract][Full Text] [Related]
18. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.
Migoya EM; Stevens CH; Bergman AJ; Luo WL; Lasseter KC; Dilzer SC; Davies MJ; Wagner JA; Herman GA
Can J Clin Pharmacol; 2009; 16(1):e165-70. PubMed ID: 19221403
[TBL] [Abstract][Full Text] [Related]
19. The effect of hepatic impairment on the pharmacokinetics of asunaprevir, an HCV NS3 protease inhibitor.
Eley T; He B; Chang I; Colston E; Child M; Bedford W; Kandoussi H; Pasquinelli C; Marbury TC; Bertz RJ
Antivir Ther; 2015; 20(1):29-37. PubMed ID: 24704773
[TBL] [Abstract][Full Text] [Related]
20. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.
Muirhead GJ; Wilner K; Colburn W; Haug-Pihale G; Rouviex B
Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):21S-30S. PubMed ID: 11879256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
